Clinical Trial: NCT04969835
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Avacta Life Sciences Ltd |
| Information Provided By: | Avacta Life Sciences Ltd |
| Last Update Posted: | 2026-10-02 |
Study Overview
Brief Summary
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Official Title
Conditions
Intervention / Treatment
- Drug: AVA6000
Other Study ID Numbers
- ALS-6000-101
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Avacta Life Sciences Ltd |
| Information Provided By: | Avacta Life Sciences Ltd |
| Last Update Posted: | 2026-10-02 |
Study Overview
Brief Summary
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Official Title
Conditions
Intervention / Treatment
- Drug: AVA6000
Other Study ID Numbers
- ALS-6000-101